NEW YORK (GenomeWeb News) - Luminex has granted EMD Chemicals, a subsidiary of Germany’s Merck KGaA, a license to develop multiplex immunoassays for the xMAP technology platform, EMD said last week.
EMD said it plans to develop multiplex assays for the xMAP under its Novagen brand to detect the phosphorylation status of proteins in disease-related signaling pathways.
EMD’s VP of corporate development, Lisa Johnson, said the advantages of multiplex protein analysis include the ability to perform different assays on one sample in single reaction results, which saves time and samples and reduces labor and reagent costs.
Financial terms of the agreement were not released.